Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT02039752
Recruiting Observational

Asan Multivessel Registry

NCT02039752 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seung-Jung Park
Phase
Observational
Started
2014-03
Last updated
2026-01-02

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

Treatment

Study summary

The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with multivessel disease from 1995 in Asan Medical Center * Age 19 and more Exclusion Criteria: * For prospective cohort, not agreeing to participate with written informed consent form

Primary outcome measure(s)

  • composite event — 1year
    death, myocardial infarction, stroke, revascularization

Trial sites (1)

FacilityCityRegionStatus
Asan Medical Center Seoul South Korea Recruiting

More Seung-Jung Park trials in South Korea

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention Recruiting
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice Recruiting
Observational Study for Left Main Disease Treatment Recruiting
IRIS-Onyx Cohort in the IRIS-DES Registry Active, not recruiting
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease Recruiting

Other trials for the same condition

Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease Active, not recruiting
The COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique Recruiting
CREATE Trial, Prospective, Observational Study Active, not recruiting
Study of the Natural History of FFR Guided Percutaneous Coronary Intervention Recruiting
Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02039752 on ClinicalTrials.gov ↗ ← All trials in South Korea